Regenerative nanomedicine and the treatment of degenerative retinal diseases

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 4, Issue 1, 2012, Pages 113-137

  Zarbin, Marco A ^a   Montemagno, Carlo ^b   Leary, James F ^c   Ritch, Robert ^d  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b University of Cincinnati   (United States)

^c PURDUE UNIVERSITY   (United States)

^d NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED MATERIALS; BIONANOTECHNOLOGY; CELL BEHAVIORS; CELL-BASED THERAPY; EXTRACELLULAR MATRICES; GENE TRANSCRIPTION FACTORS; IN-VIVO; NEURAL INTERFACES; NEURAL PROGENITOR CELLS; NEURAL PROSTHETIC; REGENERATIVE MEDICINE; RETINAL DISEASE;

CELLS; DISEASE CONTROL; DRUG THERAPY; GENE THERAPY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; OPHTHALMOLOGY; TISSUE; TRANSCRIPTION; TRANSCRIPTION FACTORS;

DISEASES;

GLUCOCORTICOID; LIPOSOME; MACROGOL; NANOMATERIAL; NANOPARTICLE; PLASMID DNA; RAPAMYCIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; TISSUE SCAFFOLD;

CELL FUNCTION; CELL THERAPY; CELL TRANSPLANTATION; DEGENERATIVE DISEASE; EXTRACELLULAR MATRIX; GENE THERAPY; GLAUCOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NANOBIOTECHNOLOGY; NANOTECHNOLOGY; NEUROPROSTHESIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE STRESS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN ENGINEERING; REGENERATIVE MEDICINE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SITE DIRECTED MUTAGENESIS; UVEORETINITIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARTIFICIAL ORGANS; BIONICS; HUMANS; NANOMEDICINE; PROSTHESES AND IMPLANTS; RABBITS; REGENERATIVE MEDICINE; RETINA; RETINAL DISEASES;

EID: 83655211698     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.167     Document Type: Review

References (212)

1. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol 2010, 150:144.e2-162.e2.
2. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanotechnology in ophthalmology. Can J Ophthalmol 2010, 45:457-476.
3. Leary JF. Nanotechnology: what is it and why is small so big? Can J Ophthalmol 2010, 45: 449-456.
4. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004, 303: 1352-1355.
5. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006, 7:65-74.
6. Patolsky F, Timko BP, Yu G, Fang Y, Greytak AB, Zheng G, Lieber CM. Detection, stimulation, and inhibition of neuronal signals with high-density nanowire transistor arrays. Science 2006, 313:1100-1104.
7. Kotov NA, Winter JO, Clements IP, Kotov NA, Winter JO, Clements IP, Jan E, Timko BP, Campidelli S, Pathak S, Mazzatenta A, Lieber CM, Prato M, et al. Nanomaterials for neural interfaces. Adv Mater 2009, 21: 3970-4004.
8. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
9. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
10. Chen X, Kube DM, Cooper MJ, Davis PB. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther 2008, 16:333-342.
11. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20:2591-2593.
12. Hamad I, Christy Hunter A, Rutt KJ, Liu Z, Dai H, Moein Moghimi S. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol 2008, 45:3797-3803.
13. Yokoe J, Sakuragi S, Yamamoto K, Teragaki T, Ogawara K, Higaki K, Katayama N, Kai T, Sato M, Kimura T. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008, 353:28-34.
14. Furumoto K, Yokoe J, Ogawara K, Amano S, Takaguchi M, Higaki K, Kai T, Kimura T. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2007, 329:110-116.
15. Renschler MF, Bhatt RR, Dower WJ, Levy R. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci U S A 1994, 91: 3623-3627.
16. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59: 748-758.
17. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90:604-610.
18. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 1996, 388:115-118.
19. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
20. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 2008, 8:2559-2563.
21. Wagstaff KM, Jans DA. Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 2009, 10:1188-1198.
22. Ferreira L, Park H, Choe H, Kohane D, Langer R. Human embryoid bodies containing nano- and micro-particulate delivery vehicles. Adv Mat 2008, 20: 2285-2291.
23. Sakai T, Kuno N, Takamatsu F, Kimura E, Kohno H, Okano K, Kitahara K. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci 2007, 48: 3381-3387.
24. Vollrath D, Feng W, Duncan JL, Yasumura D, D'Cruz PM, Chappelow A, Matthes MT, Kay MA, LaVail MM. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci U S A 2001, 98:12584-12589.
25. Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, Apfelstedt-Sylla E, Vollrath D. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 2000, 26:270-271.
26. Charbel Issa P, Bolz HJ, Ebermann I, Domeier E, Holz FG, Scholl HP. Characterisation of severe rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Br J Ophthalmol 2009, 93:920-925.
27. Mackay DS, Henderson RH, Sergouniotis PI, Li Z, Moradi P, Holder GE, Waseem N, Bhattacharya SS, Aldahmesh MA, Alkuraya FS, et al. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Mol Vis 2010, 16:369-377.
28. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90:262-267.
29. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 2007, 13:1783-1792.
30. Fu K, Harrell R, Zinski K, Um C, Jaklenec A, Frazier J, Lotan N, Burke P, Klibanov AM, Langer R. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 2003, 92:1582-1591.
31. Dalkara D, Kolstad KD, Guerin KI, Hoffmann NV, Visel M, Klimczak RR, Schaffer DV, Flannery JG. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther 2011, 19:1602-1608.
32. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003, 112:1788-1790.
33. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003, 37:471-480.
34. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001, 7:243-246.
35. Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA. Oxidative damage in age-related macular degeneration. Histol Histopathol 2007, 22: 1301-1308.
36. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007, 213: 809-815.
37. Papp A, Nemeth I, Karg E, Papp E. Glutathione status in retinopathy of prematurity. Free Radic Biol Med 1999, 27:738-743.
38. Deshpande S, Patil S, Kuchibhatla SV, Seal S. Size dependency variation in lattice parameter and valency states in nanocrystalline cerium oxide. Appl Phys Lett 2005, 87:133113.
39. 2-x nanocrystalline particles. Appl Surf Sci 1999, 152:53-56.
40. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006, 1:142-150.
41. Zhou X, Wong LL, Karakoti AS, Seal S, McGinnis JF. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the vldlr knockout mouse. PLoS One 2011, 6:e16733.
42. Truong SN, Alam S, Zawadzki RJ, Choi SS, Telander DG, Park SS, Werner JS, Morse LS. High resolution fourier-domain optical coherence tomography of retinal angiomatous proliferation. Retina 2007, 27:915-925.
43. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, 3rd, Friedman SM, Glassman AR, Miller KM, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117: 1064.e35-1077.e35.
44. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431.
45. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
46. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: Buckminsterfullerene. Nature 1985, 318: 162-163.
47. Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW, Lin TS. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A 1997, 94:9434-9439.
48. Shichi H. Microsomal electron transfer system of bovine retinal pigment epithelium. Exp Eye Res 1969, 8:60-68.
49. Yau KW, Baylor DA. Cyclic GMP-activated conductance of retinal photoreceptor cells. Annu Rev Neurosci 1989, 12:289-327.
50. Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005, 102: 12413-12418.
51. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984, 219:1-14.
52. Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch Ophthalmol 2003, 121:1099-1105.
53. Rogers BS, Symons RC, Komeima K, Shen J, Xiao W, Swaim ME, Gong YY, Kachi S, Campochiaro PA. Differential sensitivity of cones to iron-mediated oxidative damage. Invest Ophthalmol Vis Sci 2007, 48:438-445.
54. Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, Dunaief JL. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci U S A 2004, 101:13850-13855.
55. Dunaief JL, Richa C, Franks EP, Schultze RL, Aleman TS, Schenck JF, Zimmerman EA, Brooks DG. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology 2005, 112:1062-1065.
56. Chowers I, Wong R, Dentchev T, Farkas RH, Iacovelli J, Gunatilaka TL, Medeiros NE, Presley JB, Campochiaro PA, Curcio CA, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2006, 47:2135-2140.
57. He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R, Massaro-Giordano M, Dunaief JL. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 2007, 26:649-673.
58. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006, 406:189-193.
59. Gullapalli VK, Khodair M, Wang H, Sugino IK, Madreperla S, Zarbin MA. Retinal pigment epithelium and photoreceptor transplantation frontiers. In: SJ Ryan, ed. Retina. 4th ed. Philadelphia, PA: Mosby, Inc; 2006, 2597-2613.
60. Zarbin MA. Functionalizing cell-based therapy for age-related maculardegeneration. Am J Ophthalmol 2007, 143:681-682.
61. Zarbin MA. Retinal pigment epithelium-retina transplantation for retinal degenerative disease. Am J Ophthalmol 2008, 146:151-153.
62. Yuan XB, Yuan YB, Jiang W, Liu J, Tian EJ, Shun HM, Huang DH, Yuan XY, Li H, Sheng J. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008, 349:241-248.
63. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, McLeod DS, Uno K, Mennon M, Rodriguez L, Leong K, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008, 4:340-349.
64. Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol 2003, 15:6.
65. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007, 340:126-133.
66. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y, Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006, 82: 657-663.
67. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84:493-498.
68. Ishihara T, Kubota T, Choi T, Takahashi M, Ayano E, Kanazawa H, Higaki M. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int J Pharm 2009, 375:148-154.
69. Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011, 52:1516-1521.
70. Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010, 51:3575-3582.
71. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005, 6:299-310.
72. Kutsuzawa K, Chowdhury EH, Nagaoka M, Maruyama K, Akiyama Y, Akaike T. Surface functionalization of inorganic nano-crystals with fibronectin and E-cadherin chimera synergistically accelerates trans-gene delivery into embryonic stem cells. Biochem Biophys Res Commun 2006, 350:514-520.
73. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007, 13:746-757.
74. Prow T, Grebe R, Merges C, Smith JN, McLeod DS, Leary JF, Lutty GA. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis 2006, 12:616-625.
75. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res 2008, 48:319-324.
76. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006, 1:e38.
77. Ferreira L, Karp JM, Nobre L, Langer R. New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 2008, 3:136-146.
78. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.
79. Incani V, Tunis E, Clements BA, Olson C, Kucharski C, Lavasanifar A, Uludag H. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. J Biomed Mater Res A 2007, 81:493-504.
80. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004, 15:1255-1269.
81. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 2003, 20:576-583.
82. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010, 24:1178-1191.
83. Flannery JG ZS, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997, 94:6916-6921.
84. Li Q, Timmers AM, Guy J, Pang J, Hauswirth WW. Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res 2008, 48:332-338.
85. Porrello K, Bhat SP, Bok D. Detection of interphotoreceptor retinoid binding protein (IRBP) mRNA in human and cone-dominant squirrel retinas by in situ hybridization. J Histochem Cytochem 1991, 39:171-176.
86. Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 2004, 279:19064-19073.
87. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 2009, 4:e5290.
88. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, Gollomb G, Behar-Cohen FF. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005, 11:124-132.
89. Conley SM, Cai X, Naash MI. Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther 2008, 10:456-463.
90. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010, 29:376-397.
91. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25:1771-1777.
92. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2000, 97:12758-12763.
93. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-2248.
94. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.
95. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang JJ, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009, 20:999-1004.
96. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011, 12:316-328.
97. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
98. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
99. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010, 21:704-712.
100. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999, 59:406-411.
101. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
102. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009, 108:778-790.
103. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-347.
104. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007, 13:419-422.
105. Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 2008, 15:54-60.
106. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-990.
107. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2005, 2:43.
108. Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res 2008, 48: 353-359.
109. Yang GS, Schmidt M, Yan Z, Lindbloom JD, Harding TC, Donahue BA, Engelhardt JF, Kotin R, Davidson BL. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 2002, 76:7651-7660.
110. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008, 15:808-816.
111. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003, 10:964-976.
112. Ivics Z, Izsvak Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA 2010, 1:25.
113. Calos MP. The phiC31 integrase system for gene therapy. Curr Gene Ther 2006, 6:633-645.
114. Kwon I, Schaffer DV. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 2008, 25:489-499.
115. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006, 24:198-204.
116. Zhao H, Giver L, Shao Z, Affholter JA, Arnold FH. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol 1998, 16:258-261.
117. Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009, 17:2088-2095.
118. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS One 2009, 4:e7467.
119. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, Steinberg RH. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998, 39:592-602.
120. Chaum E. Retinal neuroprotection by growth factors: a mechanistic perspective. J Cell Biochem 2003, 88:57-75.
121. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006, 103:3896-3901.
122. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L, Agbandje-McKenna M, Srivastava A. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007, 15:1323-1330.
123. Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, Kube DM, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998, 72: 9835-9843.
124. Zhong L, Zhou X, Li Y, Qing K, Xiao X, Samulski RJ, Srivastava A. Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther 2008, 16:290-295.
125. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Jr., Weigel-Van Aken KA, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008, 105:7827-7832.
126. Wang W, Malcolm BA. Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis. Biotechniques 1999, 26:680-682.
127. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003, 10:2112-2118.
128. Yokoi K, Kachi S, Zhang HS, Gregory PD, Spratt SK, Samulski RJ, Campochiaro PA. Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci 2007, 48:3324-3328.
129. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005, 12:1072-1082.
130. Min SH, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, Janssen A, Tonagel F, Tanimoto N, Weber BH, Molday RS, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 2005, 12: 644-651.
131. Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009, 17:463-471.
132. Streilein JW. Limitations in the study of immune privilege in the subretinal space of the rodent. Invest Ophthalmol Vis Sci 1999, 40:3069.
133. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008, 14:1760-1769.
134. Jones BW, Watt CB, Frederick JM, Baehr W, Chen CK, Levine EM, Milam AH, Lavail MM, Marc RE. Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 2003, 464:1-16.
135. Lamba DA, Gust J, Reh TA. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009, 4:73-79.
136. Lamba DA, Karl MO, Reh TA. Strategies for retinal repair: cell replacement and regeneration. Prog Brain Res 2009, 175:23-31.
137. Lamba DA, Karl MO, Ware CB, Reh TA. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci U S A 2006, 103:12769-12774.
138. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One 2010, 5:e8763.
139. Ikeda H, Osakada F, Watanabe K, Mizuseki K, Haraguchi T, Miyoshi H, Kamiya D, Honda Y, Sasai N, Yoshimura N, et al. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci U S A 2005, 102:11331-11336.
140. Osakada F, Ikeda H, Mandai M, Wataya T, Watanabe K, Yoshimura N, Akaike A, Sasai Y, Takahashi M. Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. Nat Biotechnol 2008, 26:215-224.
141. Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, Takahashi M. Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett 2009, 458:126-131.
142. Osakada F, Jin ZB, Hirami Y, Ikeda H, Danjyo T, Watanabe K, Sasai Y, Takahashi M. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci 2009, 122:3169-3179.
143. Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cell 2006, 24:274-283.
144. Seiler MJ, Aramant RB, Thomas BB, Peng Q, Sadda SR, Keirstead HS. Visual restoration and transplant connectivity in degenerate rats implanted with retinal progenitor sheets. Eur J Neurosci 2010, 31: 508-520.
145. MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, Swaroop A, Sowden JC, Ali RR. Retinal repair by transplantation of photoreceptor precursors. Nature 2006, 444:203-207.
146. Gust J, Reh TA. Adult donor rod photoreceptors integrate into the mature mouse retina. Invest Ophthalmol Vis Sci 2011, 52:5266-5272.
147. Tomita M, Lavik E, Klassen H, Zahir T, Langer R, Young MJ. Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cell 2005, 23: 1579-1588.
148. Scadden DT. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
149. Sugino IK, Gullapalli VK, Sun Q, Wang J, Nunes CF, Cheewatrakoolpong N, Johnson AC, Degner BC, Hua J, Liu T, et al. Cell-deposited matrix improves retinal pigment epithelium survival on aged submacular human bruch's membrane. Invest Ophthalmol Vis Sci 2011, 52:1345-1358.
150. Steedman MR, Tao SL, Klassen H, Desai TA. Enhanced differentiation of retinal progenitor cells using microfabricated topographical cues. Biomed Microdevices 2010, 12:363-369.
151. Recknor JB, Sakaguchi DS, Mallapragada SK. Directed growth and selective differentiation of neural progenitor cells on micropatterned polymer substrates. Biomaterials 2006, 27:4098-4108.
152. 2 nanotube diameter directs cell fate. Nano Lett 2007, 7:1686-1691.
153. Chua KN, Chai C, Lee PC, Tang YN, Ramakrishna S, Leong KW, Mao HQ. Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells. Biomaterials 2006, 27: 6043-6051.
154. Dalby MJ, McCloy D, Robertson M, Wilkinson CD, Oreffo RO. Osteoprogenitor response to defined topographies with nanoscale depths. Biomaterials 2006, 27:1306-1315.
155. Mooney DJ, Vandenburgh H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2008, 2:205-213.
156. Ellis-Behnke RG, Liang YX, You SW, Tay DK, Zhang S, So KF, Schneider GE. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci U S A 2006, 103: 5054-5059.
157. Hynes SR, Lavik EB. A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space. Graefes Arch Clin Exp Ophthalmol 2010, 248:763-778.
158. Lavik EB, Klassen H, Warfvinge K, Langer R, Young MJ. Fabrication of degradable polymer scaffolds to direct the integration and differentiation of retinal progenitors. Biomaterials 2005, 26: 3187-3196.
159. Tao S, Young C, Redenti S, Zhang Y, Klassen H, Desai T, Young MJ. Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space. Lab Chip 2007, 7:695-701.
160. Redenti S, Tao S, Yang J, Gu P, Klassen H, Saigal S, Desai T, Young MJ. Retinal tissue engineering using mouse retinal progenitor cells and a novel biodegradable, thin-film poly(e-caprolactone) nanowire scaffold. J Ocul Biol Dis Infor 2008, 1:19-29.
161. Sodha S, Wall K, Redenti S, Klassen H, Young MJ, Tao SL. Microfabrication of a three-dimensional polycaprolactone thin-film scaffold for retinal progenitor cell encapsulation. J Biomater Sci Polym Ed 2011, 22:443-456.
162. Tao SL, Desai TA. Micromachined devices: the impact of controlled geometry from cell-targeting to bioavailability. J Control Release 2005, 109:127-138.
163. Milam AH, Li ZY, Fariss RN. Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res 1998, 17:175-205.
164. Lakhanpal RR, Yanai D, Weiland JD, Fujii GY, Caffey S, Greenberg RJ, de Juan E, Jr., Humayun MS. Advances in the development of visual prostheses. Curr Opin Ophthalmol 2003, 14:122-127.
165. Chen SJ, Mahadevappa M, Roizenblatt R, Weiland J, Humayun M. Neural responses elicited by electrical stimulation of the retina. Trans Am Ophthalmol Soc 2006, 104:252-259.
166. Zrenner E. Will retinal implants restore vision? Science 2002, 295:1022-1025.
167. Weiland JD, Liu W, Humayun MS. Retinal prosthesis. Annu Rev Biomed Eng 2005, 7:361-401.
168. Banghart M, Borges K, Isacoff E, Trauner D, Kramer RH. Light-activated ion channels for remote control of neuronal firing. Nat Neurosci 2004, 7: 1381-1386.
169. Choi SY, Sheng Z, Kramer RH. Imaging light-modulated release of synaptic vesicles in the intact retina: retinal physiology at the dawn of the post-electrode era. Vision Res 2005, 45:3487-3495.
170. Szobota S, Gorostiza P, Del Bene F, Wyart C, Fortin DL, Kolstad KD, Tulyathan O, Volgraf M, Numano R, Aaron HL, et al. Remote control of neuronal activity with a light-gated glutamate receptor. Neuron 2007, 54:535-345.
171. Volgraf M, Gorostiza P, Numano R, Kramer RH, Isacoff EY, Trauner D. Allosteric control of an ionotropic glutamate receptor with an optical switch. Nat Chem Biol 2006, 2:47-52.
172. Nagel G, Szellas T, Huhn W, Kateriya S, Adeishvili N, Berthold P, Ollig D, Hegemann P, Bamberg E. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S A 2003, 100:13940-13945.
173. Bi A, Cui J, Ma YP, Olshevskaya E, Pu M, Dizhoor AM, Pan ZH. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006, 50:23-33.
174. Lagali PS, Balya D, Awatramani GB, Munch TA, Kim DS, Busskamp V, Cepko CL, Roska B. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci 2008, 11:667-675.
175. Tomita H, Sugano E, Yawo H, Ishizuka T, Isago H, Narikawa S, Kugler S, Tamai M. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci 2007, 48:3821-3826.
176. Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature 1990, 347:677-680.
177. D'Cruz PM, Yasumura D, Weir J, Matthes MT, Abderrahim H, LaVail MM, Vollrath D. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 2000, 9:645-651.
178. Zhang Y, Ivanova E, Bi A, Pan ZH. Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. J Neurosci 2009, 29:9186-9196.
179. Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA, Arman AC, Janani R, Boye SE, Boye SL, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011, 19:1220-1229.
180. Marc RE, Jones BW, Watt CB, Vazquez-Chona F, Vaughan DK, Organisciak DT. Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration. Mol Vis 2008, 14: 782-806.
181. Strettoi E, Pignatelli V, Rossi C, Porciatti V, Falsini B. Remodeling of second-order neurons in the retina of rd/rd mutant mice. Vision Res 2003, 43:867-877.
182. Gargini C, Terzibasi E, Mazzoni F, Strettoi E. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J Comp Neurol 2007, 500:222-238.
183. Greenberg KP, Pham A, Werblin FS. Differential targeting of optical neuromodulators to ganglion cell soma and dendrites allows dynamic control of center-surround antagonism. Neuron 2011, 69: 713-720.
184. Busskamp V, Duebel J, Balya D, Fradot M, Viney TJ, Siegert S, Groner AC, Cabuy E, Forster V, Seeliger M, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010, 329: 413-417.
185. Gorostiza P, Isacoff EY. Nanoengineering ion channels for optical control. Physiology (Bethesda) 2008, 23:238-247.
186. Fortin DL, Banghart MR, Dunn TW, Borges K, Wagenaar DA, Gaudry Q, Karakossian MH, Otis TS, Kristan WB, Trauner D, et al. Photochemical control of endogenous ion channels and cellular excitability. Nat Methods 2008, 5:331-338.
187. Caporale N, Kolstad KD, Lee TD, Tochitsky I, Dalkara D, Trauner D, Kramer RH, Dan Y, Isacoff EY, Flannery JG. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther 2011, 19:1212-1219.
188. Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, Dacruz L, Stanga P, Humayun MS, Greenberg RJ. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol 2011, 95:539-543.
189. Winter JO, Han N, Jensen R, Cogan SF, Rizzo JF. Adhesion molecules promote chronic neural interfaces following neurotrophin withdrawal. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:7151-7154.
190. Kelly SK, Shire DB, Chen J, Doyle P, Gingerich MD, Drohan WA, Theogarajan LS, Cogan SF, Wyatt JL, Rizzo JF, 3rd. Realization of a 15-channel, hermetically-encased wireless subretinal prosthesis for the blind. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:200-203.
191. Zrenner E, Bartz-Schmidt KU, Benav H, Besch D, Bruckmann A, Gabel VP, Gekeler F, Greppmaier U, Harscher A, Kibbel S, et al. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci 2011, 278:1489-1497.
192. Julien S, Peters T, Ziemssen F, Arango-Gonzalez B, Beck S, Thielecke H, Buth H, Van Vlierberghe S, Sirova M, Rossmann P, et al. Implantation of ultrathin, biofunctionalized polyimide membranes into the subretinal space of rats. Biomaterials 2011, 32:3890-3898.
193. Fujikado T, Kamei M, Sakaguchi H, Kanda H, Morimoto T, Ikuno Y, Nishida K, Kishima H, Maruo T, Konoma K, et al. Testing of semi-chronically implanted retinal prosthesis by suprachoroidal-transretinal stimulation in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2011, 52:4726-4733.
194. Finlayson PG, Iezzi R. Glutamate stimulation of retinal ganglion cells in normal and s334ter-4 rat retinas: a candidate for a neurotransmitter-based retinal prosthesis. Invest Ophthalmol Vis Sci 2010, 51:3619-3628.
195. Lovric J, Cho SJ, Winnik FM, Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 2005, 12:1227-1234.
196. Lovric J, Bazzi HS, Cuie Y, Fortin GR, Winnik FM, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med 2005, 83:377-385.
197. Chan WH, Shiao NH, Lu PZ. CdSe quantum dots induce apoptosis in human neuroblastoma cells via mitochondrial-dependent pathways and inhibition of survival signals. Toxicol Lett 2006, 167:191-200.
198. Choi AO, Cho SJ, Desbarats J, Lovric J, Maysinger D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnology 2007, 5:1.
199. Maysinger D, Behrendt M, Lalancette-Hebert M, Kriz J. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 2007, 7:2513-2520.
200. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004, 112:1058-1062.
201. Kim DH, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 2006, 27:3031-3037.
202. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, Bergey EJ, Prasad PN, Stachowiak MK. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A 2005, 102:11539-11544.
203. Zou LL, Huang L, Hayes RL, Black C, Qiu YH, Perez-Polo JR, Le W, Clifton GL, Yang K. Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. Gene Ther 1999, 6:994-1005.
204. Green RA, Lovell NH, Wallace GG, Poole-Warren LA. Conducting polymers for neural interfaces: challenges in developing an effective long-term implant. Biomaterials 2008, 29:3393-3399.
205. Abidian MR, Kim D-H, Martin DC. Conducting-polymer nanotubes for controlled drug release. Adv Mater 2006, 18:405-409.
206. Kim D-H, Richardson-Burns SM, Hendricks JL, Sequera C, Martin DC. Effect of immobilized nerve growth factor on conductive polymers: electrical properties and cellular responses. Adv Func Mater 2007, 17:79-86.
207. Cui X, Lee VA, Raphael Y, Wiler JA, Hetke JF, Anderson DJ, Martin DC. Surface modification of neural recording electrodes with conducting polymer/biomolecule blends. J Biomed Mater Res 2001, 56:261-272.
208. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277: 1232-1237.
209. Gheith MK, Pappas TC, Lioppo AV, Sinani VA, Shim BS, Motamedi M, Wicksted JP, Kotov NA. Stimulation of neural cells by lateral currents in conductive layer-by-layer films of single-walled carbon nanotubes. Adv Mater 2006, 18:2975-2979.
210. Sinani VA, Koktysh DS, Yun B-G, Matts RL, Pappas TC, Motamedi M, Thomas SN, Kotov NA. Collagen coating promotes biocompatibility of semiconductor nanoparticles in stratified LBL films. Nano Lett 2003, 3:1177-1183.
211. Pappas TC, Wickramanyake WM, Jan E, Motamedi M, Brodwick M, Kotov NA. Nanoscale engineering of a cellular interface with semiconductor nanoparticle films for photoelectric stimulation of neurons. Nano Lett 2007, 7:513-519.
212. Feynman R. There's plenty of room at the bottom. Eng Sci 1960, 23:22-36.